MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Demographic and Clinical Characteristics and Tetrabenazine (TBZ) Persistence in Patients With Huntington Disease (HD)-Associated Chorea

    V. Sung, R. Iyer, S. Gandhi, V. Abler, B. Davis, D. Irwin, K. Anderson (Birmingham, AL, USA)

    Objective: To characterize demographic and clinical characteristics of HD patients with chorea based on TBZ use status, and to examine treatment persistence with TBZ in…
  • 2017 International Congress

    Parkinsonism in the very old – A clinicopathological study

    A. Rajput, E. Rajput (Saskatoon, SK, Canada)

    Objective: To identify, spectrum of Parkinson variants, clinical features and course of disease in age > 80 year onset cases. Background: Old age is the…
  • 2017 International Congress

    Regulation of aberrant striatal oscillations by glutamate receptor blockade in parkinsonian non-human primates

    A. Singh, S. Papa (Minneapolis, MN, USA)

    Objective: To study the abnormal striatal oscillations and regulation of striatal oscillatory activities by micro-infusion of glutamate receptor antagonist in the non-human primate model of…
  • 2017 International Congress

    Interaction between PLK2 ( Polo-like kinase-2) and alpha-synuclein in the non-human primate MPTP model of Parkinson disease

    R. Valenti-Azcarate, I. Martinez-Valbuena, M.-M. Carmona-Abellan, I. Marcilla-Garcia, G. Marti-Andres, M.R. Luquin-Piudo (Pamplona, Spain)

    Objective: The objective is to determine the levels and interactions between PLK2  and one of its main substrates, synuclein, in the non-human primate MPTP model of…
  • 2017 International Congress

    Targeted overexpression of A53T-alpha-synuclein induces progressive neurodegeneration and electrophysiological changes of noradrenergic locus coeruleus neurons – a preclinical model of Parkinson’s disease

    M. Henrich, L. Matschke, A. Stoehr, W.-H. Chiu, B. Lee, F. Geibl, J. Koprich, N. Decher, W. Oertel (Marburg, Germany)

    Objective: In our present study, we developed a new mouse model to study the time dependent effects of cellular A53T-α-synuclein overexpression in the locus coeruleus,…
  • 2017 International Congress

    Prognostic relevance and predictive ability of data-driven PD subtypes in the Longitudinal and Biomarker Studies in Parkinson’s disease (LABS-PD)

    T. Mestre, S. Eberly, C. Tanner, D. Grimes, A. Lang, D. Oakes, C. Marras (Ottawa, ON, Canada)

    Objective: To assess the prognostic relevance and predictive ability of a PD subtype classification system generated in LABS-PD cohort. Background: PD subtype classification systems have…
  • 2017 International Congress

    Evaluation of Swallowing Function in Parkinson’s Disease Patients with and without Dysphagia Complaints

    E. Umay, E. Ozturk, I. Gundogdu, O. Delibas, A. Cakci, B. Gonenli, Y. Eren (Ankara, Turkey)

    Objective: To assess swallowing functions of symptomatic and asymptomatic patients Parkinson's disease (PD). Background: Swallowing studies in PD without dysphagia symptoms are lacking and swallowing…
  • 2017 International Congress

    Evaluation of CSF cytokine profiles in people with Parkinson disease and age-matched controls.

    G. Crotty, D. Vaughan, G. Moloney, G. O'Keeffe, S. O'Sullivan, A. Sullivan (Cork, Ireland)

    Objective: To investigate the levels of cytokines in the cerebrospinal fluid of subjects with Parkinson disease (PD) and matched healthy controls. Background: Neuroinflammation is thought…
  • 2017 International Congress

    Saccadic impairment in patients with Gaucher’s disease type 3

    J. Blume, C. Kämpe Björkvall, M. Machaczka, P. Svenningsson (Stockholm, Sweden)

    Objective: To characterize saccades in patients with chronic neuronopathic Gaucher’s disease (GD3) in relationship to their neurological and cognitive status using a computer-based eye-tracking technique.  Background: GD3 is…
  • 2017 International Congress

    A Pair of Brothers with Aceruloplasminemia Due to a Novel Nonsense Mutation: Unusual Phenotype and Neurological Improvement After Iron-Chelation Therapy with Deferasirox.

    F. Valzania, F. Cavallieri, M. Fiorini, S. Contardi, F. Ferrara, E. Menozzi, S. Scarlini, F. Cavalleri, M. Molinari, A. Pietrangelo, E. Corradini (Modena, Italy)

    Objective: We describe the phenotype of a novel ceruloplasmin mutation and the neurological response to different iron-chelating therapies. Background: Aceruloplasminemia (AC) is a rare autosomal…
  • « Previous Page
  • 1
  • …
  • 89
  • 90
  • 91
  • 92
  • 93
  • …
  • 155
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley